Orakl Oncology raises $34M to predict cancer drug results with AI
Paris-based Orakl Oncology has raised a $34M Series A co-led by Norrsken VC and Singular. It grows copies of patients’ tumours in the lab, tests drugs on them and uses AI to predict trial results.
Reported so far by one publisher.
Summary from The Next Web.
Reporting1
The Next Web Orakl Oncology raises $34M to predict cancer drug results with AI · Ana-Maria Stanciuc